Abstract
Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have